- Home
- ACV vs GALT Comparison
ACV vs GALT Comparison
Compare ACV & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACV | GALT |
|---|---|---|
| Founded | 2015 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 272.8M | 297.0M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | ACV | GALT |
|---|---|---|
| Price | $27.16 | $3.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 26.2K | ★ 528.1K |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | ★ 9.20% | N/A |
| EPS Growth | N/A | ★ 36.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.27 | $2.03 |
| 52 Week High | $29.04 | $7.13 |
Technical Indicators
Market Signals| Indicator | ACV | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 43.36 | 43.95 |
| Support Level | $25.75 | $2.75 |
| Resistance Level | $28.27 | $3.35 |
| Average True Range (ATR) | 0.69 | 0.32 |
| MACD | 0.00 | -0.11 |
| Stochastic Oscillator | 34.82 | 28.78 |
Price Performance
Historical ComparisonAbout ACV Virtus Diversified Income & Convertible Fund of Beneficial Interest
Virtus AllianzGI Diversified Income & Convertible Fund is a diversified, limited-term, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. It invests in a diversified portfolio of convertible securities, income-producing equity securities, and income-producing debt and other instruments of varying maturities, of which a majority of the managed assets are invested in convertibles.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.